Clinical trial · Observational
Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation
A Multicentre Observational Study on Treatment Approaches and Biomarkers in de Novo Metastatic Hormone Sensitive Prostate Cancer in Russian Federation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): As a part of planned reassessment for the current period, a decision has been made to prioritize, optimize, and reallocate resources. As a result, enrollment and other study activities have been temporarily halted.
Summary
Brief summary (as posted)
A multicentre observational study on treatment approaches and biomarkers in de novo metastatic hormone sensitive prostate cancer in Russian Federation
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (12)
- measure
- Proportion of patients received any ADT
- timeFrame
- 24 months
- description
- Proportion of patients received any Androgen deprivation therapy (ADT)
- measure
- Proportion of patients received ADT by each type and by each drug
- timeFrame
- 24 months
- description
- Proportion of patients received Androgen deprivation therapy (ADT) by each type and by each drug;
- measure
- Proportion of patients received first generation antiandrogens
- timeFrame
- 24 months
- description
- Proportion of patients received first generation antiandrogens;
- measure
- Proportion of patients received ARPI at mHSPC
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male patients aged ≥ 18 years old; 2. Signed ICF, including consent for FFPE tumor tissue sample testing; 3. De novo histologically confirmed high-aggressive (Gleason 8-10) mPC; 4. Diagnosis of mPC (metastatic prostate cancer) within 2 years prior to inclusion; 5. Availability of source medical documentation; 6. Presence of biopsy FFPE tumor tissue sample, obtained as part of standard clinical practice, which will be used for biomarker testing; 7. Unknown HRRm status. Exclusion Criteria: 1\. Participation in any interventional trial since the mPC diagnosis.
References
Publications (0)
Data not yet available